Benefits of using vinpocetine Review article
Article Sidebar
Published:
Jul 22, 2024
Keywords:
vinpocetine, brain stroke, cognitive deficit, hypertension, dizziness, hearing loss, seizures, neuroprotection
Main Article Content
Abstract
Since its introduction to the market in 1978, vinpocetine has been widely used in many neurological diseases, primarily due to its cerebral vasodilator effect. Subsequent studies demonstrated its activity, showing both an anti-inflammatory effect – by inhibiting the transcription of nuclear factor κΒ (NF-κB) – as well as a strong neuroprotective activity of this substance, among others, through the ability to inhibit voltage-dependent sodium and calcium channels. Clinical trials have confirmed the beneficial therapeutic profile of vinpocetine. The benefits of using vinpocetine have been demonstrated in patients with stroke, cognitive disorders (especially associated with hypertension), and patients with mild cognitive deficits. Vinpocetine also brings beneficial effects in patients with dizziness, hearing loss, or epileptic episodes occurring in the course of diseases of the central nervous system. Due to the low number of drug interactions, vinpocetine can be used in polymodal therapy with other drugs used to treat diseases of the nervous system.
Article Details
How to Cite
Frankiewicz, T. (2024). Benefits of using vinpocetine. Medycyna Faktow (J EBM). Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/3132
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. NFZ o zdrowiu. Udar niedokrwienny mózgu. https://ezdrowie.gov.pl/portal/home/badania-i-dane/zdrowe-dane/raporty/nfz-o-zdrowiu-udar-niedokrwienny-mozgu.
2. Ahn HS, Crim W, Romano M et al. Effects of selective inhibitors on cyclic nucleotide phosphodiesterases of rabbit aorta. Biochem Pharmacol. 1989; 38: 3331-9.
3. Dong ZC, Shi Y, Juan L. Synthesis and pharmacological activity of vinpocetine derivatives. RSC Adv. 2024; 14: 7981.
4. Ahmad N, Lesa KN, Sudarmanto A. The role of Phosphodiesterase-1 and its natural product inhibitors in Alzheimer’s disease: A review. Front Pharmacol. 2022; 13: 1070677. http://doi.org/10.3389/fphar.2022.1070677.
5. Zhang YS, Li JD, Yan C. An update on vinpocetine: new discoveries and clinical implications. Eur J Pharmacol. 2018; 819: 30-4.
6. Bönöczk P, Gulyaś B, Adam-Vizi V. Role of sodium channel inhibition in neuroprotection: Effect of vinpocetine. Br Res Bull. 2000; 53(3): 245-54.
7. Jeon KI, Xu X, Aizawa T et al. Vinpocetine inhibits NF-κBdependent inflammation via an IKK-dependent but PDE-independent mechanism. Proc Natl Acad Sci USA. 20210; 107: 9795-800.
8. Lamar J-C, Poignet H, Beaughard M. Calcium antagonist activity of vinpocetine and vincamine in several models of cerebral ischaemia. Drug Dev Res. 1988; 14: 297-304.
9. Sitges M, Sanchez-Tafolla BM, Chiu LM. Vinpocetine inhibits glutamate release induced by the convulsive agent 4-aminopyridine more potently than several antiepileptic drugs. Epilepsy Res. 2011; 96: 257-66.
10. Salińska E, Danysz W, Łazarewicz W. The role of excitotoxicity in neurodegeneration. Folia Neuropathol. 2005; 43(4): 322-39.
11. Santos MS, Durate AI, Moreira PI. Synaptosomal response to oxidative stress: Effect of vinpocetine. Free Radical Res. 2000; 32: 57-66.
12. Hadjiev D, Yancheva S. Rheoencephalographic and psychological studies with etyl apovincaminate in cerebral vascular insufficiency. Drug Res. 1976; 26: 1947-50.
13. Solti F, Iskum M, Czako E. Effect of ethyl apovincaminate on the cerebral circulation. Drug Res. 1976; 26: 1945-7.
14. Valikovics A. [Investigation of the effect of vinpocetine on cerebral blood flow and cognitive functions]. Ideggyogy Sz. 2007; 60 (7-8): 301-10.
15. Werner J, Apecechea M, Schaltenbrand R et al. Clinical study to evaluate the efficacy and tolerance of vinpocetine i.v. added to standard therapy in patients suffering from an acute apoplectic insult Senile Dementias: early detection. John Libbey Eurotext. 1986; 1: 636-41.
16. Fenzl E, Apecechea M, Schaltenbrand R. Efficacy and tolerance of vinpocetine administered intravenously, in addition of standard therapy, to patients suffering from an apoplectic insult. W: Pharmacology of Cerebral Ischemia. Proceedings of the International Symposium on Pharmacology of Cerebral Ischemia. Krieglstein J (ed). Elsevier, New York 1986; 430-434.
17. Blaha L, Erzigkeit H, Adamczyk A. Clinical evidence of the effectiveness of vinpocetine in the treatment of organic psychosyndrome. Human Psychopharmacology. 1989; 4: 103-111.
18. Hindmarch I, Fuchs HH, Erzigkeit H. Efficacy and tolerance of vinpocetine in ambulant patients suffering from mild to moderate organic psychosyndromes. Int Clin Psychopharmacol. 1991; 6(1): 31-43.
19. Macrez R, Ali C, Toutirais O et al. Stroke and the immune system: from pathophysiology to new therapeutic strategies. Lancet Neurol. 2011; 10: 471-80.
20. Zarruk JG, Greenhalgh AD, David S. Microglia and macrophages differ in their inflammatory profile after permanent brain ischemia. Exp Neurol. 2018; 301: 120-32.
21. Wu LR, Liu L, Xiong XY et al. Vinpocetine alleviate cerebral ischemia/reperfusion injury by down-regulating TLR4/MyD88/NF-κB signaling. Oncotarget. 2017; 8: 80315-24.
22. Zhang F, Yan C, Wei C. Vinpocetine Inhibits NF-κB-Dependent Inflammation in Acute Ischemic Stroke Patients. Transl Stroke Res. 2018; 9: 174-184.
23. Mamcarz A, Mastalerz-Migas A, Mirowska-Guzel D. Stanowisko interdyscyplinarnego zespołu ekspertów dotyczące leczenia pacjentów z nadciśnieniem tętniczym i współistniejącymi zaburzeniami funkcji poznawczych w codziennej praktyce lekarskiej. Lekarz POZ. 2017; 3(6): 369-82.
24. Taiji H. Clinical study of vinpocetine in the treatment of vertigo. Pharmacology and Treatment. 1986; 14(2): 577-89.
25. Smartsev IN, Zhivolupov SA, Butakova S. Efficiency of long-term vinpocetine administration in the treatment of dizziness and associated statodynamic disorders in patients with chronic cerebrovascular insufficiency (EDELWEISS study). 2019; 11(1): 36-47.
26. Garza-Morales S, Briceno-Gonzalez, Ceja-Moreno E. Extended-release vinpocetine: a possible adjuvant treatment for focal onset epileptic seizures. Bol Med Hosp Infant Mex. 2019; 76(5): 215-24.
27. Gjerulfsen CE, Mieszczanek TS , Johannsen KM. Vinpocetine improved neuropsychiatric and epileptic outcomes in a patient with a GABRA1 loss-of-function variant. Ann Clin Transl Neurol. 2023; 10(8): 1493-8.
28. Jasper A. Action of cavinton on hearing defects of different origin. Hung Med. 1978; 26: 181-4.
29. Gutierrez-Farfan I, Reyes-Legoreta C, Solis-Olguin M. Evaluation of vinpocetine as a therapy in patients with sensorineural hearing loss: A phase II, open-label, single-center study. J Pharmacol Sci 2021;145: 313-18.
30. Panda PK, Ramachandran A, Panda P. Safety and Efficacy of Vinpocetine as a Neuroprotective Agent in Acute Ischemic Stroke: A Systematic Review and Meta‑Analysis. Neurocrit Care. 2022; 37: 314-25.
2. Ahn HS, Crim W, Romano M et al. Effects of selective inhibitors on cyclic nucleotide phosphodiesterases of rabbit aorta. Biochem Pharmacol. 1989; 38: 3331-9.
3. Dong ZC, Shi Y, Juan L. Synthesis and pharmacological activity of vinpocetine derivatives. RSC Adv. 2024; 14: 7981.
4. Ahmad N, Lesa KN, Sudarmanto A. The role of Phosphodiesterase-1 and its natural product inhibitors in Alzheimer’s disease: A review. Front Pharmacol. 2022; 13: 1070677. http://doi.org/10.3389/fphar.2022.1070677.
5. Zhang YS, Li JD, Yan C. An update on vinpocetine: new discoveries and clinical implications. Eur J Pharmacol. 2018; 819: 30-4.
6. Bönöczk P, Gulyaś B, Adam-Vizi V. Role of sodium channel inhibition in neuroprotection: Effect of vinpocetine. Br Res Bull. 2000; 53(3): 245-54.
7. Jeon KI, Xu X, Aizawa T et al. Vinpocetine inhibits NF-κBdependent inflammation via an IKK-dependent but PDE-independent mechanism. Proc Natl Acad Sci USA. 20210; 107: 9795-800.
8. Lamar J-C, Poignet H, Beaughard M. Calcium antagonist activity of vinpocetine and vincamine in several models of cerebral ischaemia. Drug Dev Res. 1988; 14: 297-304.
9. Sitges M, Sanchez-Tafolla BM, Chiu LM. Vinpocetine inhibits glutamate release induced by the convulsive agent 4-aminopyridine more potently than several antiepileptic drugs. Epilepsy Res. 2011; 96: 257-66.
10. Salińska E, Danysz W, Łazarewicz W. The role of excitotoxicity in neurodegeneration. Folia Neuropathol. 2005; 43(4): 322-39.
11. Santos MS, Durate AI, Moreira PI. Synaptosomal response to oxidative stress: Effect of vinpocetine. Free Radical Res. 2000; 32: 57-66.
12. Hadjiev D, Yancheva S. Rheoencephalographic and psychological studies with etyl apovincaminate in cerebral vascular insufficiency. Drug Res. 1976; 26: 1947-50.
13. Solti F, Iskum M, Czako E. Effect of ethyl apovincaminate on the cerebral circulation. Drug Res. 1976; 26: 1945-7.
14. Valikovics A. [Investigation of the effect of vinpocetine on cerebral blood flow and cognitive functions]. Ideggyogy Sz. 2007; 60 (7-8): 301-10.
15. Werner J, Apecechea M, Schaltenbrand R et al. Clinical study to evaluate the efficacy and tolerance of vinpocetine i.v. added to standard therapy in patients suffering from an acute apoplectic insult Senile Dementias: early detection. John Libbey Eurotext. 1986; 1: 636-41.
16. Fenzl E, Apecechea M, Schaltenbrand R. Efficacy and tolerance of vinpocetine administered intravenously, in addition of standard therapy, to patients suffering from an apoplectic insult. W: Pharmacology of Cerebral Ischemia. Proceedings of the International Symposium on Pharmacology of Cerebral Ischemia. Krieglstein J (ed). Elsevier, New York 1986; 430-434.
17. Blaha L, Erzigkeit H, Adamczyk A. Clinical evidence of the effectiveness of vinpocetine in the treatment of organic psychosyndrome. Human Psychopharmacology. 1989; 4: 103-111.
18. Hindmarch I, Fuchs HH, Erzigkeit H. Efficacy and tolerance of vinpocetine in ambulant patients suffering from mild to moderate organic psychosyndromes. Int Clin Psychopharmacol. 1991; 6(1): 31-43.
19. Macrez R, Ali C, Toutirais O et al. Stroke and the immune system: from pathophysiology to new therapeutic strategies. Lancet Neurol. 2011; 10: 471-80.
20. Zarruk JG, Greenhalgh AD, David S. Microglia and macrophages differ in their inflammatory profile after permanent brain ischemia. Exp Neurol. 2018; 301: 120-32.
21. Wu LR, Liu L, Xiong XY et al. Vinpocetine alleviate cerebral ischemia/reperfusion injury by down-regulating TLR4/MyD88/NF-κB signaling. Oncotarget. 2017; 8: 80315-24.
22. Zhang F, Yan C, Wei C. Vinpocetine Inhibits NF-κB-Dependent Inflammation in Acute Ischemic Stroke Patients. Transl Stroke Res. 2018; 9: 174-184.
23. Mamcarz A, Mastalerz-Migas A, Mirowska-Guzel D. Stanowisko interdyscyplinarnego zespołu ekspertów dotyczące leczenia pacjentów z nadciśnieniem tętniczym i współistniejącymi zaburzeniami funkcji poznawczych w codziennej praktyce lekarskiej. Lekarz POZ. 2017; 3(6): 369-82.
24. Taiji H. Clinical study of vinpocetine in the treatment of vertigo. Pharmacology and Treatment. 1986; 14(2): 577-89.
25. Smartsev IN, Zhivolupov SA, Butakova S. Efficiency of long-term vinpocetine administration in the treatment of dizziness and associated statodynamic disorders in patients with chronic cerebrovascular insufficiency (EDELWEISS study). 2019; 11(1): 36-47.
26. Garza-Morales S, Briceno-Gonzalez, Ceja-Moreno E. Extended-release vinpocetine: a possible adjuvant treatment for focal onset epileptic seizures. Bol Med Hosp Infant Mex. 2019; 76(5): 215-24.
27. Gjerulfsen CE, Mieszczanek TS , Johannsen KM. Vinpocetine improved neuropsychiatric and epileptic outcomes in a patient with a GABRA1 loss-of-function variant. Ann Clin Transl Neurol. 2023; 10(8): 1493-8.
28. Jasper A. Action of cavinton on hearing defects of different origin. Hung Med. 1978; 26: 181-4.
29. Gutierrez-Farfan I, Reyes-Legoreta C, Solis-Olguin M. Evaluation of vinpocetine as a therapy in patients with sensorineural hearing loss: A phase II, open-label, single-center study. J Pharmacol Sci 2021;145: 313-18.
30. Panda PK, Ramachandran A, Panda P. Safety and Efficacy of Vinpocetine as a Neuroprotective Agent in Acute Ischemic Stroke: A Systematic Review and Meta‑Analysis. Neurocrit Care. 2022; 37: 314-25.